tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RYTM Stock Latest News

Rhythm Pharmaceuticals Advances Obesity Treatment with RM-718 Study
Company AnnouncementsRhythm Pharmaceuticals Advances Obesity Treatment with RM-718 Study
10h ago
RYTM
Rhythm Pharmaceuticals Updates Exculpation Provision in Charter
PremiumCompany Announcements
Rhythm Pharmaceuticals Updates Exculpation Provision in Charter
1d ago
8K
RYTM
Rhythm Pharmaceuticals announces three data abstracts accepted for ENDO 2025
PremiumThe Fly
Rhythm Pharmaceuticals announces three data abstracts accepted for ENDO 2025
3d ago
RYTM
Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments
PremiumRatings
Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Promising Pipeline and Strategic Developments
23d ago
RYTM
Buy Rating for Rhythm Pharmaceuticals: Promising Outlook for Bivamelagon in Treating Hypothalamic Obesity
PremiumRatings
Buy Rating for Rhythm Pharmaceuticals: Promising Outlook for Bivamelagon in Treating Hypothalamic Obesity
24d ago
RYTM
Rhythm Pharmaceuticals: Promising Growth Potential with Setmelanotide and Strategic Pipeline Advancements
PremiumRatingsRhythm Pharmaceuticals: Promising Growth Potential with Setmelanotide and Strategic Pipeline Advancements
30d ago
RYTM
Rhythm Pharmaceuticals price target raised to $94 from $78 at Stifel
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $94 from $78 at Stifel
30d ago
RYTM
Buy Rating for Rhythm Pharmaceuticals Driven by Promising IMCIVREE Outlook and Potential Market Expansion
Premium
Ratings
Buy Rating for Rhythm Pharmaceuticals Driven by Promising IMCIVREE Outlook and Potential Market Expansion
1M ago
RYTM
Rhythm Pharmaceuticals announces presentations on setmelanotide
PremiumThe Fly
Rhythm Pharmaceuticals announces presentations on setmelanotide
1M ago
RYTM
Buy Rating Affirmed for Rhythm Pharmaceuticals on Promising Setmelanotide Data and Positive Outlook
PremiumRatings
Buy Rating Affirmed for Rhythm Pharmaceuticals on Promising Setmelanotide Data and Positive Outlook
2M ago
RYTM
Buy Rating for Rhythm Pharmaceuticals Driven by Promising Prospects of IMCIVREE and Expansion into Hypothalamic Obesity
PremiumRatings
Buy Rating for Rhythm Pharmaceuticals Driven by Promising Prospects of IMCIVREE and Expansion into Hypothalamic Obesity
2M ago
RYTM
Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals
PremiumRatings
Robust Pipeline and Regulatory Progress Bolster Buy Rating for Rhythm Pharmaceuticals
2M ago
RYTM
Strong Growth Potential for Rhythm Pharmaceuticals: Buy Rating Affirmed by Michael Ulz
PremiumRatingsStrong Growth Potential for Rhythm Pharmaceuticals: Buy Rating Affirmed by Michael Ulz
2M ago
RYTM
Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Promising Outlook for Setmelanotide and Strong Growth Prospects
Premium
Ratings
Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Promising Outlook for Setmelanotide and Strong Growth Prospects
2M ago
RYTM
Promising Growth Outlook for Rhythm Pharmaceuticals Driven by Key Program Developments and Strong Market Performance
Premium
Ratings
Promising Growth Outlook for Rhythm Pharmaceuticals Driven by Key Program Developments and Strong Market Performance
2M ago
RYTM
Rhythm Pharmaceuticals Reports Strong Q1 2025 Results
PremiumCompany Announcements
Rhythm Pharmaceuticals Reports Strong Q1 2025 Results
2M ago
RYTM
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Strong Outlook
PremiumCompany Announcements
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Strong Outlook
2M ago
RYTM
Positive Outlook for Rhythm Pharmaceuticals Amid Strong Imcivree Demand and Promising Phase III Trial Results
PremiumRatings
Positive Outlook for Rhythm Pharmaceuticals Amid Strong Imcivree Demand and Promising Phase III Trial Results
2M ago
RYTM
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Promising Developments and Future Growth Potential
PremiumRatings
Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Promising Developments and Future Growth Potential
2M ago
RYTM
Rhythm Pharmaceuticals reports Q1 EPS (81c), consensus (68c)
PremiumThe FlyRhythm Pharmaceuticals reports Q1 EPS (81c), consensus (68c)
2M ago
RYTM
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Results and Market Expansion Plans
Premium
Ratings
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Results and Market Expansion Plans
2M ago
RYTM
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results
Premium
Market News
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results
2M ago
RYTM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >